Abstract
In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Current Vascular Pharmacology
Title: What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Volume: 8 Issue: 6
Author(s): Giuseppe Mancia and Guido Grassi
Affiliation:
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Abstract: In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Export Options
About this article
Cite this article as:
Mancia Giuseppe and Grassi Guido, What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563942
DOI https://dx.doi.org/10.2174/157016110793563942 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews Atypical Antipsychotic Drugs During Pregnancy. Their Effects on the Mother and Offspring
Current Women`s Health Reviews Effect of Aging On Angiogenesis and Arteriogenesis
Current Cardiology Reviews Naringin Inhibits TNF-α Induced Oxidative Stress and Inflammatory Response in HUVECs via Nox4/NF-κ B and PI3K/Akt Pathways
Current Pharmaceutical Biotechnology Computational Approaches on Angiotensin Receptors and Their Ligands: Recent Developments and Results
Current Medicinal Chemistry The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Characteristic Imaging Features of Merkel Cell Carcinoma: A Case Report
Current Medical Imaging Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Inflammation, Sleep, Obesity and Cardiovascular Disease.
Current Vascular Pharmacology Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design Gut Microbiota: A New Marker of Cardiovascular Disease
Current Pharmaceutical Design Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Safety and Efficacy of Novel Oral Anticoagulants: A Comparison to Vitamin K Antagonists
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Imaging Techniques as an Aid in the Early Detection of Cardiac Amyloidosis
Current Pharmaceutical Design Meet Our Associate Editor
Cardiovascular & Hematological Disorders-Drug Targets Statins as Antihypertensives
Recent Patents on Cardiovascular Drug Discovery